Prosensa and GlaxoSmithKline expand Duchenne dystrophy alliance

24.06.10 Leiden - Prosensa NV and British drugmaker GlaxoSmithKline have expanded their cooperation concerning RNA-modulating drugs against Duchenne muscular dystrophy (DMD). Two programmes, covering 4 drug new drug candidates for... more

EU funding finder

16.05.10 Brussels – The European Biotechnology Network (www.european-biotechnology.org) kicked-off its new “Biotechnology Funding Hub” service in April. “We will bring all relevant information on funding opportunities and new funding... more

Endpoint met

12.05.10 ThromboGenics NV‘s (Leuven) recombinantly expressed protease microplasmin for pharmacological vitreolysis has met the primary endpoint in a Phase III trial including 326 patients in the US. Comparison of a single injection of... more

Pepscan spins out therapeutic vaccine portfolio to Immunovo BV

29.04.10 Lelystad/s'Hertogenbosch - Dutch immune therapeutics specialist Pepscan, has spun out its therapeutic vaccine portfolio to the firm Immunovo BV. Under the terms of the agreement, Pepscan will receive an undisclosed cash... more

FDA sends complete response letter to USB

26.04.10 Brussels – The U.S. Food and Drug Administration (FDA) has recommended reformulation of UCB SA’s Neupro (Rotigotine Transdermal System) before making it available in the U.S. for the treatment of Parkinson's disease (PD) and... more